Home Cart Sign in  
Chemical Structure| 423145-35-1 Chemical Structure| 423145-35-1

Structure of YUM70
CAS No.: 423145-35-1

Chemical Structure| 423145-35-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

YUM70 is a GRP78 inhibitor with IC50 value of 1.5μM and resulted in ER stress-mediated apoptosis. It inhibited pancreatic cancer cell growth in vitro and showed in vivo efficacy in a pancreatic cancer xenograft model with no toxicity to normal tissues.

Synonyms: YUM70

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of YUM70

CAS No. :423145-35-1
Formula : C21H19ClN2O4
M.W : 398.84
SMILES Code : CCCC(NC(C1=CC=C(OCO2)C2=C1)C3=CC(Cl)=C4C=CC=NC4=C3O)=O
Synonyms :
YUM70
MDL No. :MFCD02228856
InChI Key :BIQMEYCMAGHOEQ-UHFFFAOYSA-N
Pubchem ID :3138755

Safety of YUM70

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of YUM70

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MIA PaCa-2 10 µM 24 hours YUM70 treatment reduced c-MYC protein levels and induced apoptosis. Neoplasia. 2024 Sep;55:101020.
MDA-MB-231 10 µM 24 hours YUM70 treatment reduced c-MYC protein levels and induced apoptosis. Neoplasia. 2024 Sep;55:101020.
CisR-3 10 µM 24 hours YUM70 treatment reduced c-MYC protein level by 60% and induced apoptosis. Neoplasia. 2024 Sep;55:101020.
CisR-2 10 µM 24 hours YUM70 treatment reduced c-MYC protein level by 60% and induced apoptosis. Neoplasia. 2024 Sep;55:101020.
SCC15 10 µM 24 hours YUM70 treatment reduced c-MYC protein level by 85% and induced apoptosis. Neoplasia. 2024 Sep;55:101020.
SCC25 10 µM 24 hours YUM70 treatment reduced c-MYC protein level by 70% and induced apoptosis. Neoplasia. 2024 Sep;55:101020.
PANC-1 cells 10 µM 24 hours YUM70 significantly suppressed KRAS protein levels, induced apoptosis, and reduced cell viability Neoplasia. 2022 Nov;33:100837.
HCT116 cells 10 µM 24 hours YUM70 significantly suppressed KRAS protein levels, induced apoptosis, and reduced cell viability Neoplasia. 2022 Nov;33:100837.
H460 cells 10 µM 24 hours YUM70 significantly suppressed KRAS protein levels, induced apoptosis, and reduced cell viability Neoplasia. 2022 Nov;33:100837.
A427 cells 10 µM 24 hours YUM70 significantly suppressed KRAS protein levels, induced apoptosis, and reduced cell viability Neoplasia. 2022 Nov;33:100837.
CisR-3 10 µM 48 hours YUM70 treatment reduced the viability of cisR-3 cells with an IC50 of 10 μM and induced the expression of apoptotic markers (cleaved Caspase-7 and cleaved PARP). Front Oncol. 2023 Jan 11;12:1044699
SCC351 1.25-20 µM 48 hours YUM70 treatment led to general increase in GRP78 protein level and induced apoptotic markers (CHOP, cleaved-PARP) in all three SCC cell lines in a YUM70 dose-dependent manner. Front Oncol. 2023 Jan 11;12:1044699
SCC25 1.25-20 µM 48 hours YUM70 treatment led to general increase in GRP78 protein level and induced apoptotic markers (CHOP, cleaved-PARP) in all three SCC cell lines in a YUM70 dose-dependent manner. Front Oncol. 2023 Jan 11;12:1044699
SCC15 1.25-20 µM 48 hours YUM70 treatment led to general increase in GRP78 protein level and induced apoptotic markers (CHOP, cleaved-PARP) in all three SCC cell lines in a YUM70 dose-dependent manner. Front Oncol. 2023 Jan 11;12:1044699
Vero E6 ACE2 cells 0 to 10 µM 72 hours To investigate the inhibitory effect of YUM70 on live SARS-CoV-2 virus infection. Results showed that YUM70 efficiently inhibited both the number and size of SARS-CoV-2 plaques formed. Viruses. 2023 May 6;15(5):1118

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NCr nude mice MIA PaCa-2 xenograft model Intraperitoneal injection 25-30 mg/kg 5 days a week for 48 days YUM70 significantly suppressed tumor growth and reduced KRAS protein levels Neoplasia. 2022 Nov;33:100837.
NCr nude mice Pancreatic cancer xenograft model Intraperitoneal injection 30 mg/kg 5 days a week for 7 weeks To evaluate the in vivo antitumor efficacy of YUM70, results showed significant tumor growth delay with no toxicity to normal tissues. Cancer Res. 2021 Apr 1;81(7):1883-1895
Mice MIA PaCa-2 pancreatic cancer xenograft model Intraperitoneal injection 30 mg/kg 5 days a week for 48 days YUM70 treatment significantly reduced c-MYC protein levels in the tumors. Neoplasia. 2024 Sep;55:101020.
K18-hACE2 transgenic mice SARS-CoV-2 infection model Intraperitoneal injection 30 mg/kg Daily, starting one day before infection and five times a week post-infection To evaluate the effect of YUM70 on SARS-CoV-2 infection in mice. Results showed that YUM70 treatment led to reduced weight loss and a trend towards longer survival in infected mice. Viruses. 2023 May 6;15(5):1118

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.51mL

0.50mL

0.25mL

12.54mL

2.51mL

1.25mL

25.07mL

5.01mL

2.51mL

References

 

Historical Records

Categories